Search

Search Constraints

You searched for: Author/Creator Nagashima, Hiromi

Search Results

4. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Issue 1 (January 2022)

6. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Issue 5 (May 2019)

10. Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR‐mutated lung cancer. Issue 3 (13th December 2021)